Biocartis Group NV provided production and cash guidance for full year 2018. Guidance for the full year is narrowed to 130,000 - 135,000 commercial cartridges (approx. 90% increase year-over-year). Targeted year-end cash position further narrowed to around EUR 55 million, excluding drawdowns on the Company's multiple purpose credit facility.